Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application Updates
    • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Featured Therapy
    • Research (White Papers)
    • Survivor Stories
      • Brew (Dog)
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • Research (White Papers)
    • US FDA IDE Application Updates
    • US FDA IDE Pre-Submission Process
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Featured Therapy
    • Research (White Papers)
    • Survivor Stories
      • Brew (Dog)
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Vivos Inc.
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
    July 06, 2023

    Vivos Inc. Q2 2023 Update | IsoPet® - RadioGel™

    • VX-2 Animal Study Completed | New IsoPet® Clinic fully licensed and operational

    We are pleased to share quarterly progress updates on the following items:

    Human Sector - RadioGel™

    Food and Drug Administration Path to an IDE Submittal

     

    • We completed the VX2/Rabbit Animal Study and are now writing the comprehensive report, which will be included in the final IDE(1) submission.

     

    • As previously mentioned we met with the FDA in an IDE Pre-Sub meeting this past April 10th. They now want us to focus on genotoxicity(2).

     

    • We engaged IUVO Bioscience(3) to perform scoping studies and to write the genotoxicity(2) testing protocol.

      The week of July 14th we will submit the protocol request to the FDA; for review at a future Pre-Sub meeting as they recommended. In addition we will request a review of our comprehensive Risk Management report, which concludes that RadioGel™ is intrinsically safe.
    • 1). FDA approval of an IDE is required for human study of a significant risk device which is not approved for the indication being studied.
    • 2). Genotoxicity refers to the capability of a substance to damage the genetic information of cells (changes of the structure, sequence, and/or number of genes) 
    • 3). About: iuvo is headquartered in Rush, NY and maintains a 30,000-square-foot preclinical laboratory testing facility that offers an on-site AAALAC accredited vivarium and specialty testing services for the medical device and pharmaceutical industries. iuvo has a talented team whose breadth of testing and consulting expertise spans multiple disciplines including Analytical Chemistry, Microbiology, Toxicology, and Sterilization Validation.  Our experience is particularly deep serving the ophthalmics industry, including OTCs, drugs, devices, and combination products.

    Animal Sector - IsoPet®

    New Regional Clinics

     

    • We completed certification of the Myhre Equine Clinic in Rochester NH. June 23, 2023 they treated their first patient for a large melanoma on its tail. We have added them to our list of regional clinics.

    Our Twitter post from June 26, 2023.

    Just a brief update – last week as scheduled we conducted an IsoPet® Therapy on this #horse. We look forward to sharing results in an expanded update soon.

    Thank you.#horse #animalcancer #savinglives $RDGL https://t.co/owpGMihmPG

    — IsoPet® Solutions (@IsoPet_RadioGel) June 26, 2023

    IsoPet® is a next generation treatment option, providing a same day therapy, using relatively low activity to deliver a high therapeutic dose that stays at the injection site with no contamination in the urine or feces. 

     

    Veterinarian Dr. Michael Myhre treated the clinic’s first equine patient for a sarcoma on its tail.

     


    Marketing

     

    • Chad Smith from F.X. Massé presented at the Delaware Society for Radiation Safety, DVSRS, annual health physics meeting in Philadelphia. Chad is contracted to help with the required licensing at the regional clinics and provides the on-line certification training modules.

     

    • Dave Swanberg, our Chief Technology Manager, presented at the VSPA Spring Conference in St. Louis.

     

    • We had a booth at the American College of Veterinary Internal Medicine Conference in Philadelphia, which is the largest small animal conference of the year. Fred Swindler, our Quality Assurance Manager and I attended. There was strong interest in the Precision Radionuclide Therapy (PRnT) and we obtained many new contacts. 

     

    • I am presenting a paper at the 11th International Conference on Isotopes in July in Saskatoon Canada in July.

     

    • We have booths at the Washington State Veterinary Medical Association in Tacoma, WA in September, the Veterinary Cancer Society in Reno, NV in October and at the American Association of Equine Practitioners in San Diego, CA in December.

     

    Therapy Support System Equipment

     

    • We completed the patented design on our therapy support system equipment and are now in production to send them to all our current and future regional clinics.

     

    • We refined the IsoPet® Instructions for Use, Injection Guidance Table, and its Training Guide to incorporate the latest equipment design and recommendations for process improvement, including recommending room temperature injections. This will go to all future human applications as well.

     

    Peltier Chiller | Mixer

    Peltier unit with pigs in thermal well cover

    Peltier chiller showing unit syringe swith shield pig vial holder and pig cover

    Peltier Unit with syringe with shield and pig vial holder in temperature controlled slots


    Combined shipping container (aka pig) with temperature sensor and vial holder.

    Peltier vial with RadioGel™/IsoPet® Y-90 Hydrogel.

    Note: This Y-90 suspension is now non-radioactive and used for display purposes only. 

    the pig/vial with a temperature strip attached

    Note: This Y-90 suspension is now non-radioactive
    and used for display purposes only. 


    The pig/vial containers are transparent acrylic. They are designed to ship the IsoPet® solution, and stay in the container. All shown with nylon lid threaded shoulder screw. The nylon screw is removed, and the patented hydrogel withdrawn by a syringe; once again serving as a radiation shield. 

    Advisory Boards

     

    We reconstituted and strengthened our Veterinary Medicine and Medical advisory boards. They continue to provide valuable senior guidance. 

     

    Financial

     

    The 2nd Quarter 10-Q was been filed on schedule.

     

    Thank you for your continued support. 

     

    Mike Korenko, Sc. D

    CEO & President Vivos Inc.

    CONTACT:
    Vivos Inc.
    Michael K. Korenko, Sc.D.
    President & CEO

    tagPlaceholderTags:

    Vivos, Inc.

    Precision Radionuclide Therapy (PRnT)

    OTCQB: RDGL

    contact: info@radiogel.com


    Home Page Cover Image: 

     

    Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

     

    Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

    RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

    IsoPet® Therapy Application(s)


    Precision Radionuclide Therapy (PRnT)


    Vivos Inc.
     - (OTCQB: RDGL) Investor Relations 

    Contact

     

    Main colors
       bg-primary
       bg-primary-light
       bg-primary-dark
       bg-secondary
       bg-secondary-dark
    Template sections
       body
       top-header
       header
       content
    Footer Styles
       background
       text color
       link color
       horizontal line
    Buttons
       style 1
       style 2
       style 3
    Other elements
      social icons
      navigation color
      subnav background
    Mobile navigation
       background color
       navigation color
    Template configurations
    has-right-nav g-font
    navigation styles
    size-15 weight-400 snip-nav
    content styles
    form-white
    footer styles
    o-form color-white
    Typography
    Heading H1
    weight-600
    Heading H2
    weight-600
    Heading H3
    weight-600
    Buttons
    weight-600 is-uppercase
    Animations

    Note:
    All changes made here will be applied to your entire website.
    is-switcher admin-only

    RadioGel™ Logo

    Precision Radionuclide Therapy™ (PRnT)

    draggable-logo

    About | Privacy Policy | Cookie Policy | Sitemap
    © 2023 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
    Log out | Edit
    • Scroll to top